000143705 001__ 143705
000143705 005__ 20240229112605.0
000143705 0247_ $$2doi$$a10.1038/s41573-019-0016-5
000143705 0247_ $$2pmid$$apmid:30760888
000143705 0247_ $$2ISSN$$a1474-1776
000143705 0247_ $$2ISSN$$a1474-1784
000143705 0247_ $$2altmetric$$aaltmetric:55401339
000143705 037__ $$aDKFZ-2019-01278
000143705 041__ $$aeng
000143705 082__ $$a610
000143705 1001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b0$$eFirst author$$udkfz
000143705 245__ $$aTryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.
000143705 260__ $$aLondon$$bNature Publ. Group$$c2019
000143705 3367_ $$2DRIVER$$aarticle
000143705 3367_ $$2DataCite$$aOutput Types/Journal article
000143705 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1652167290_7791$$xReview Article
000143705 3367_ $$2BibTeX$$aARTICLE
000143705 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143705 3367_ $$00$$2EndNote$$aJournal Article
000143705 520__ $$aL-Tryptophan (Trp) metabolism through the kynurenine pathway (KP) is involved in the regulation of immunity, neuronal function and intestinal homeostasis. Imbalances in Trp metabolism in disorders ranging from cancer to neurodegenerative disease have stimulated interest in therapeutically targeting the KP, particularly the main rate-limiting enzymes indoleamine-2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan-2,3-dioxygenase (TDO) as well as kynurenine monooxygenase (KMO). However, although small-molecule IDO1 inhibitors showed promise in early-stage cancer immunotherapy clinical trials, a phase III trial was negative. This Review summarizes the physiological and pathophysiological roles of Trp metabolism, highlighting the vast opportunities and challenges for drug development in multiple diseases.
000143705 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000143705 588__ $$aDataset connected to CrossRef, PubMed,
000143705 7001_ $$aNollen, Ellen A A$$b1
000143705 7001_ $$00000-0002-4676-4087$$aRöhrig, Ute F$$b2
000143705 7001_ $$00000-0002-8501-2136$$aFallarino, Francesca$$b3
000143705 7001_ $$0P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34$$aOpitz, Christiane$$b4$$eLast author$$udkfz
000143705 773__ $$0PERI:(DE-600)2061062-2$$a10.1038/s41573-019-0016-5$$gVol. 18, no. 5, p. 379 - 401$$n5$$p379 - 401$$tNature reviews / Drug discovery Drug discovery [...]$$v18$$x1474-1784$$y2019
000143705 8564_ $$uhttps://inrepo02.dkfz.de/record/143705/files/Platt_Tryptophan_Neu.pdf$$yOpenAccess
000143705 8564_ $$uhttps://inrepo02.dkfz.de/record/143705/files/Platt_Tryptophan_Neu.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000143705 909CO $$ooai:inrepo02.dkfz.de:143705$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000143705 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143705 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143705 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000143705 9141_ $$y2019
000143705 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143705 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143705 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143705 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT REV DRUG DISCOV : 2017
000143705 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143705 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143705 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143705 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143705 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143705 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000143705 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143705 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000143705 915__ $$0StatID:(DE-HGF)9950$$2StatID$$aIF >= 50$$bNAT REV DRUG DISCOV : 2017
000143705 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143705 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143705 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143705 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lNeuroimmunologie und Hirntumorimmunologie$$x0
000143705 9201_ $$0I:(DE-He78)B350-20160331$$kB350$$lMetabolischer Crosstalk bei Krebserkrankungen$$x1
000143705 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000143705 980__ $$ajournal
000143705 980__ $$aVDB
000143705 980__ $$aUNRESTRICTED
000143705 980__ $$aI:(DE-He78)D170-20160331
000143705 980__ $$aI:(DE-He78)B350-20160331
000143705 980__ $$aI:(DE-He78)L101-20160331
000143705 9801_ $$aFullTexts